【摘要】 目的:探讨树突状细胞(dendritic cells,DCs)-细胞因子诱导的杀伤细胞(cytokine induced killer,CIK)免疫治疗联合经导管动脉化学栓塞(transcatheter arterial chemoembolization,TACE)在原发性肝癌治疗中的临床疗效及不良反应。方法:以2013年1月—2015年3月收治的52例原发性肝癌患者为研究对象,影像学上有可见病灶,但无远处转移,所有患者经TACE治疗,按照是否联合DCs-CIK免疫治疗将其分为对照组(TACE单独治疗)27例与观察组(TACE联合DCs-CIK细胞免疫治疗)25例;比较2组患者的临床疗效、无进展生存(progression-free survival,PFS)、总生存(overall survival,OS)、1年生存率、生活质量及免疫治疗后不良反应的发生情况。结果:观察组的临床总有效率为80.0%,明显高于对照组的66.7%,差异具有统计学意义(P<0.05)。观察组的平均PFS时间为(15.61±4.34)个月、平均生存时间为(21.53±6.37)个月、1年生存率为84.0%(21/25),均明显高于对照组的(11.26±5.08)个月、(15.95±5.25)个月和62.9%(17/27),差异具有统计学意义(P值均<0.05)。治疗后,观察组的躯体功能、角色功能、认知功能、情绪功能及社会功能得分均明显高于对照组,差异具有统计学意义(P值均<0.05)。观察组在治疗中出现发热3例,腹痛1例,胃肠系统反应1例。结论:在原发性肝癌治疗中开展DCs-CIK免疫治疗联合TACE治疗,能够明显改善患者的生活质量,改善生存,而且治疗安全性较高,值得在临床中推广应用。更多还原

【Abstract】 Objective:To explore the clinical efficacy and adverse reactions of immunotherapy with dendritic cells(DCs)-cytokine-induced killer(CIK) in combination with transcatheter arterial chemoembolization(TACE) in treatment of primary liver cancer.Methods:Fifty-two patients with primary liver cancer between January 2013 and March 2015 were included in this study.All patients had radiological findings of liver cancer without distant metastasis,and they were divided into TACE group(n = 27) and TACE combined with DCs-CIK group(n = 25).The overall response rate,progression-free survival(PFS),overall survival(OS),1-year survival rate,quality of life and adverse reactions induced by DCs-CIK were compared between the two groups.Results:The overall response rate of TACE combined with DCs-CIK group was significantly higher than that of TACE group(80.0%vs 66.7%,P < 0.05).The mean PFS time,mean survival time and 1-year survival of TACE combined with DCs-CIK group were 15.61 ±4.34 months,21.53+6.37 months,and 84.0%,respectively,which were significantly higher than those of TACE group(11.26±5.08 months,1 5.95 + 5.25 months,and 62.9%,repectively;all P < 0.05).After treatment,the physical function,role function,cognitive function,emotional function and social function scores of TACE combined with DCs-CIK group were significantly higher than those of TACE group(all P < 0.05).There were 3 cases of fever,1 case of abdominal pain and 1 case of gastrointestinal reaction observed in TACE combined with DCs-CIK group.Conclusion:Treatment with combination of DCs-CIK and TACE is safety and can improve the quality of life and survival of patients with primary liver cancer,and it is worthy of clinical promotion and application.更多还原